Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 25.0 1.01% 0.25
ACOR closed up 1.01 percent on Thursday, January 18, 2018, on 1.95 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ACOR trend table...

Date Alert Name Type % Chg
Jan 18 Shooting Star Candlestick Bearish 0.00%
Jan 18 Lizard Bearish Bearish Day Trade Setup 0.00%
Jan 18 Doji - Bearish? Reversal 0.00%
Jan 18 Upper Bollinger Band Walk Strength 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Upper Bollinger Band Touch Strength 0.00%
Jan 17 Upper Bollinger Band Walk Strength 1.01%
Jan 17 Wide Bands Range Expansion 1.01%
Jan 16 Bearish Engulfing Bearish -0.20%
Jan 16 New Uptrend Bullish -0.20%

Older signals for ACOR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jan 17 FINAL SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018
Jan 17 Kessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER:  Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACOR
Jan 16 DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
Jan 16 FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018
Jan 15 ACOR UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018
Jan 15 IMPORTANT STOCKHOLDER NOTICE: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Stockholders That Important Deadline Nears
Jan 14 SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
Jan 12 SHAREHOLDER REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Class Action Lawsuit Filed against Acorda Therapeutics, Inc.
Jan 11 IMPORTANT SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Shareholders That Important Deadline Nears
Jan 11 ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in Class Action – ACOR
See more ACOR news...
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 13.6
Average Volume 863,706
200-Day Moving Average 20.9133
50-Day Moving Average 22.368
20-Day Moving Average 22.985
10-Day Moving Average 24.08
Average True Range 1.3555
ADX 27.57
+DI 33.51
-DI 12.7
Chandelier Exit (Long, 3 ATRs ) 22.9335
Chandelier Exit (Short, 3 ATRs ) 24.5665
Upper Bollinger Band 26.0609
Lower Bollinger Band 19.9091
Percent B (%b) 0.83
BandWidth 26.764412
MACD Line 0.89
MACD Signal Line 0.5715
MACD Histogram 0.3185
Fundamentals Value
Market Cap 1.16 Billion
Num Shares 46.6 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -26.60
Price-to-Sales 2.27
Price-to-Book 1.76
PEG Ratio 0.51
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.90
Resistance 3 (R3) 29.13 28.07 28.25
Resistance 2 (R2) 28.07 27.07 27.95 28.03
Resistance 1 (R1) 26.53 26.46 27.30 26.30 27.82
Pivot Point 25.47 25.47 25.85 25.35 25.47
Support 1 (S1) 23.93 24.47 24.70 23.70 22.18
Support 2 (S2) 22.87 23.86 22.75 21.97
Support 3 (S3) 21.33 22.87 21.75
Support 4 (S4) 21.10